Kluwer Patent Blog

AstraZeneca, General Court EU, 1 July 2010

Peter Burgers (Brinkhof) · Monday, July 19th, 2010

The General Court upheld, for the most part, the decision of the European Commission in AstraZeneca. The Court held that AstraZeneca infringed Article 82 EC (prohibition of abuse of a dominant market position) in so far as AstraZeneca requested the registration of Losec capsules market authorisations in Norway and Denmark.

The Court further held that the possession of intellectual property rights can create, in certain circumstances, a dominant position, especially when enabling an undertaking to prevent effective competition on the market.

A full summary of this case has been published on Kluwer IP Law.

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how Kluwer IP Law can support you.


1

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law. The master resource for Intellectual Property rights and registration.





2022 SURVEY REPORT The Wolters Kluwer Future Ready Lawyer Leading change

This entry was posted on Monday, July 19th, 2010 at 1:47 pm and is filed under Case Law, European Union, SPC

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.